Skip to main content
EMVISION MEDICAL DEVICES LTD logo

EMVISION MEDICAL DEVICES LTD — Investor Relations & Filings

Ticker · EMV ISIN · AU0000028375 ASX Manufacturing
Open in API
Filings indexed 304 across all filing types
Latest filing 2020-05-05 Board/Management Inform…
Country AU Australia
Listing ASX EMV

About EMVISION MEDICAL DEVICES LTD

https://emvision.com.au/

EMVision Medical Devices Ltd is a medical technology company focused on the development and commercialization of portable medical imaging devices. The company specializes in electromagnetic microwave imaging technology designed for the rapid diagnosis and monitoring of stroke and traumatic brain injury. Its primary product is a portable brain scanner intended for use at the point of care, including intensive care units, emergency departments, and ambulances. By utilizing non-ionizing radiation, the technology provides a safe, cost-effective, and mobile alternative to traditional neuroimaging modalities like CT and MRI. The device aims to facilitate earlier clinical intervention by enabling bedside assessment, potentially improving patient outcomes through faster detection of ischemic and hemorrhagic strokes.

Recent filings

Filing Released Lang Actions
Dr Ron Weinberger Appointed Managing Director 2 pages 155.2KB
Board/Management Information Classification · 95% confidence The document is an announcement regarding changes in the company's board and senior management, specifically the appointment of Dr. Ron Weinberger as Managing Director and changes in the Chairman role. It includes details about the terms of engagement and option grants related to the appointment. There are no financial statements, earnings data, or detailed financial analysis present. The content focuses on management changes and governance updates. Therefore, the document fits the category of Board/Management Information (MANG). The document length (6361 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2020-05-05 English
Initial Director's Interest Notice 2 pages 162.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including shares and options, and discloses interests held by the director and related parties. This is a report of personal share transactions or holdings by a company director. The document length is short and focused solely on director share interests, matching the definition of Director's Dealing filings. There is no indication of financial results, management changes, or other report types. Therefore, the document is classified as Director's Dealing (DIRS).
2020-05-05 English
Appendix 4C - quarterly 9 pages 249.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'APPENDIX 4C – 31 MARCH 2020 QUARTERLY CASHFLOW REPORT' and contains detailed quarterly cash flow statements, including cash flows from operating, investing, and financing activities. It references the quarter ended 31 March 2020 and includes substantive financial data and analysis for that period. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. Appendix 4C is a standard quarterly report format for Australian listed entities under ASX Listing Rule 4.7B, which corresponds to an Interim / Quarterly Report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2020
2020-04-29 English
Promising First Stroke Patient Images From Clinical Trial 4 pages 496.7KB
Regulatory Filings Classification · 95% confidence The document is an announcement from EMVision Medical Devices Ltd providing preliminary clinical trial results related to stroke patient imaging. It includes detailed descriptions of the clinical trial, initial data, expert comments, and a clinical trial summary appendix. The document is not a full financial report, audit, or regulatory filing. It is a company announcement focused on clinical trial progress and preliminary scientific results rather than financial or governance information. It does not contain financial statements or detailed financial analysis, nor is it a transcript or management discussion. The document is a market update on clinical trial progress, which fits best under the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit other specific categories such as Annual Report, Earnings Release, or Investor Presentation. The document length (11,454 characters) and content confirm it is a substantive announcement rather than a brief report publication notice or certification.
2020-04-20 English
Clinical Trial Update 2 pages 144.2KB
Capital/Financing Update Classification · 85% confidence The document is a clinical trial update from EMVision Medical Devices Limited, providing progress on patient enrollment, data collection, and financial status related to the clinical trial. It does not contain financial statements, audit information, or detailed management discussion of financial results. It is an operational update focused on clinical trial progress and company funding status. There is no indication that this is a full financial report, earnings release, or regulatory filing. The content is an update on ongoing clinical trial activities and company status, which aligns best with a Capital/Financing Update (CAP) since it includes funding information and operational progress relevant to investors.
2020-04-01 English
Clinical Trial Update 2 pages 147.8KB
Regulatory Filings Classification · 95% confidence The document is a clinical trial update from EMVision Medical Devices Limited, providing progress on a medical device clinical trial and the impact of COVID-19 on the trial timeline. It includes operational details about patient enrollment, data collection, and resource access, as well as a brief financial update on cash position. There are no financial statements, earnings data, or regulatory filings such as annual or interim reports. The content is an operational update related to clinical trial progress rather than a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information rather than just announcing a report release. The document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement updating the market on clinical trial progress and company status without fitting into more specific categories like earnings release or capital update.
2020-03-24 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.